THE EFFICACY OF MONODOSE VARICELLA VACCINE IN PEDIATRIC CANCER PATIENTS

Volume: 41 Number: 4 December 1, 2002
  • Suat Paker
  • Füsun Atlıhan
  • - Pamirgülez
  • Canan Vergin
  • Alpay Özbek
EN TR

THE EFFICACY OF MONODOSE VARICELLA VACCINE IN PEDIATRIC CANCER PATIENTS

Abstract

In this study the efficacy of a single dose varicella vaccine was evaluated in 20 patients with acute lymphoblastic leukemia and lymphoma. AH patients were serologically negatıve by the absence of antıvaricella antibody. AH cases were in remission for at least 6 months and their absolute lymphocyte count at the time of immunization was ≥ 700/mm3. For patients receiving maintenance therapy, chemotherapy was suspended for 1 week before and 1 week after immunization. Antıvaricella antibody concentration was determined 3 and 24 months after immunization to evaluate antibody response. İn cancer group geometric mean antibody concentration was found 42.78 HU on the 3rd month and 29.3 HU on the 24th month and in the control group the values were 45.98 HU and 31.8. The seropositivity rates were found 90% on the 3rd and on the 24th months in each group. Unserious side effects due to varicella vaccination were determined in 40% of the pediatric cancer group and in 10% of the control group. İn conclusion we can say that single dose varicella vaccine is effective and safe in patients with acute lymphoblastic leukemia and lymphoma.

Keywords

Details

Primary Language

Turkish

Subjects

-

Journal Section

-

Authors

Suat Paker

Füsun Atlıhan

- Pamirgülez

Canan Vergin

Alpay Özbek

Publication Date

December 1, 2002

Submission Date

December 1, 2002

Acceptance Date

-

Published in Issue

Year 2002 Volume: 41 Number: 4

Vancouver
1.Suat Paker, Füsun Atlıhan, - Pamirgülez, Canan Vergin, Alpay Özbek. KANSERLİ HASTALARDA TEK DOZ SUÇİÇEĞİ AŞISININ ETKİNLİĞİ. EJM [Internet]. 2002 Dec. 1;41(4):225-8. Available from: https://izlik.org/JA79PR47NB

Ege Journal of Medicine enables the sharing of articles according to the Attribution-Non-Commercial-Share Alike 4.0 International (CC BY-NC-SA 4.0) license.